shield therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- shield therapeutics's estimated annual revenue is currently $18.5M per year.
- shield therapeutics's estimated revenue per employee is $201,000
Employee Data
- shield therapeutics has 92 Employees.
- shield therapeutics grew their employee count by 2% last year.
shield therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP, Quality, Clinical and Regulatory Affairs | Reveal Email/Phone |
3 | Head Pharmacovigilance and Medical Information | Reveal Email/Phone |
4 | Director Product Supply & CMC | Reveal Email/Phone |
5 | Corporate and Communications Director | Reveal Email/Phone |
6 | Senior Manager, People Systems and Operations | Reveal Email/Phone |
7 | Iron Specialist | Reveal Email/Phone |
8 | Group Financial Controller | Reveal Email/Phone |
9 | Territory Sales Specialist | Reveal Email/Phone |
shield therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is shield therapeutics?
Shield is a de-risked commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid2030s. Feraccru® is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27 July 2019.
keywords:N/A
N/A
Total Funding
92
Number of Employees
$18.5M
Revenue (est)
2%
Employee Growth %
N/A
Valuation
N/A
Accelerator